Skip to search formSkip to main contentSkip to account menu

Nucleoside Reverse Transcriptase Inhibitors [MoA]

Known as: Nucleoside Reverse Transcriptase Inhibitors 
National Institutes of Health

Related topics

Related topics

22 relations
DidanosineHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]Lamivudine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
The rate of virological failure was assessed in 386 adult patients attending the Centre National Hospitalier Universitaire of… 
Highly Cited
2010
Highly Cited
2010
Synthesis, nanosizing and in vitro drug release of a novel anti-HIV polymeric prodrug: chitosan-O-isopropyl-5'-O-d4T monophosphate conjugate.
Review
2005
Review
2005
Insertions in the Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Genes: Clinical Impact and Molecular Mechanisms
Treatment of human immunodeficiency virus (HIV) type 1 (HIV-1)-infected individuals with antiretroviral (ARV) drugs is highly… 
Highly Cited
2003
Highly Cited
2003
Atp Binding Cassette Multidrug Transporters Limit the Anti-HIV Activity of Zidovudine and Indinavir in Infected Human Macrophages
Objectives To investigate whether P-glycoprotein (P-gp) and multidrug resistance proteins (MRPs), which limit the bioavailability… 
2003
2003
HIV-1 Resistance Profile of the Novel Nucleoside Reverse Transcriptase Inhibitor β-D-2′,3′-Dideoxy-2′,3′-Didehydro-5-Fluorocytidine (Reverset™)
Nucleoside reverse transcriptase inhibitors (NRTIs) represent the cornerstone of highly active antiretroviral therapy when… 
Highly Cited
2002
Highly Cited
2002
First‐line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48‐week results
To evaluate safety and efficacy of the protease inhibitor combination ritonavir/indinavir 100/800 mg twice daily plus 2–3… 
Review
2002
Review
2002
Genetic mechanisms of resistance to NRTI and NNRTI
Abstract Resistance to nucleoside reverse trascriptase inhibitors (NRTIs) seems to develop following three different pathways… 
Highly Cited
2000
Highly Cited
2000
Prevalence of Transmitted Nucleoside Analogue-Resistant HIV-1 Strains and Pre-Existing Mutations in Pol Reverse Transcriptase and Protease Region: Outcome after Treatment in Recently Infected…
We retrospectively studied 38 Italian recently HIV-1-infected subjects who seroconverted from 1994 to 1997 to investigate: (i… 
Review
2000
Review
2000
Lack of Evidence of Mitochondrial Dysfunction in the Offspring of HIV‐Infected Women: Retrospective Review of Perinatal Exposure to Antiretroviral Drugs in the Perinatal AIDS Collaborative…
Abstract: A recent report suggesting mitochondrial dysfunction among eight HIV‐exposed but uninfected children exposed… 
Highly Cited
1998
Highly Cited
1998
Activity of a ritonavir plus saquinavir‐containing regimen in patients with virologic evidence of indinavir or ritonavir failure
Objective:To evaluate the virologic activity of a ritonavir plus saquinavir–containing regimen in patients who have failed an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)